Regeneron Faces Securities Class Action Over Failed Clinical Trial

The lawsuit, filed in the United States District Court for the Southern District of New York, centers on allegations that Regeneron misled shareholders by minimizing significant statistical and protocol risks associated with its Fianlimab-Libtayo study. Plaintiffs contend that the company failed to adequately disclose that slowing event accrual indicated potential clinical failure rather than durable efficacy. Furthermore, the complaint claims that Regeneron neglected to inform investors that the study’s active treatment arm struggled to demonstrate meaningful differentiation compared to standard therapies like pembrolizumab.

Market volatility followed disclosures regarding these study design issues. After the company announced a protocol amendment to expand the progression-free survival analysis population and subsequently revealed that the trial failed to meet its primary endpoint, Regeneron shares dropped 13.95%. The stock fell from a class-period high of $731.77 on April 28, 2026, to $629.68 by mid-May. Attorneys representing the class argue that generic risk warnings provided by the company were insufficient to cover the specific regulatory and statistical vulnerabilities identified during the trial process.